Cargando…
Evaluation of Data Errors and Monitoring Activities in a Trial in Japan Using a Risk-Based Approach Including Central Monitoring and Site Risk Assessment
BACKGROUND: Risk-based monitoring (RBM) is a slow uptake in some trial sponsors. There are three main reasons for this. First, there is the fear of making large investments into advanced RBM technology solutions. Second, it is considered that RBM is most suitable for large, complex trials. Third, th...
Autores principales: | Kondo, Hidenobu, Kamiyoshihara, Tomoaki, Fujisawa, Kenji, Nojima, Toshiaki, Tanigawa, Ryohei, Fujiwara, Hisataka, Suganami, Hideki, Hayashi, Yukikazu, Yamaguchi, Takuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238712/ https://www.ncbi.nlm.nih.gov/pubmed/33876398 http://dx.doi.org/10.1007/s43441-021-00286-9 |
Ejemplares similares
-
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
por: Nakajima, Atsushi, et al.
Publicado: (2021) -
Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial
por: Tsujita, Kenichi, et al.
Publicado: (2023) -
Error monitoring in musicians
por: Maidhof, Clemens
Publicado: (2013) -
Personality and error monitoring: an update
por: Hoffmann, Sven, et al.
Publicado: (2012) -
Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study
por: Terauchi, Yasuo, et al.
Publicado: (2019)